COMMUNIQUÉS West-GlobeNewswire
-
Starget Pharma Expands Scientific Advisory Board with Appointment of Two Global Leaders in Radiopharmaceutical Therapy
28/07/2026 -
Tensive reports pivotal 12-month clinical trial data confirming REGENERA™ delivers natural breast reconstruction after lumpectomy
28/07/2026 -
Aqua free soutient un projet d’accès à l’eau potable en Tanzanie
28/07/2026 -
Aqua free Supports Drinking Water Project in Tanzania
28/07/2026 -
Xeltis raises an additional €20.5m of funding to advance aXess™ toward FDA approval and US commercial launch
28/07/2026 -
Promatix Biosciences Awarded Innovate UK Biomedical Catalyst Grant to Advance First-in-Class EGFR × EphA2 Cis-Bispecific ADC
28/07/2026 -
Transactions in connection with share buy-back program
28/07/2026 -
Rapid Nutrition Expands Owned-Brand Portfolio Through AI-Driven Commercial Intelligence
28/07/2026 -
Picard Medical / SynCardia to Present Next-Generation Emperor Total Artificial Heart Technology at IEEE EMBC 2026
27/07/2026 -
Legacy Health Works LLC Announces Kylar Denae Williams, 2024 University of Arkansas Graduate, as Chief Executive Officer of the Family-Built, AI-Infused Healthcare Company
28/07/2026 -
CG Oncology Announces Publication of Pivotal Phase 3 BOND-003 Cohort C Study Results in The Lancet Oncology
28/07/2026 -
BurnTide Launch 2026: New Weight Loss Support ACV Gummies In The USA, AU, UK | Burntide Supplement Facts And Highlights Ingredients.
28/07/2026 -
ARCPOINT PROVIDES UPDATE ON MANAGEMENT CEASE TRADE ORDER APPLICATION AND DELAY IN FILING ANNUAL FINANCIAL STATEMENTS
28/07/2026 -
Elevar Therapeutics Announces Three Abstracts Accepted for Presentation at ESMO Congress 2026
27/07/2026 -
ORYZON Reports Financial Results and Corporate Update for Half Year Ended June 30th, 2026
27/07/2026 -
Philips delivers solid comparable sales growth and margin in Q2; reiterates full year comparable sales growth outlook; Adjusted EBITA and free cash flow outlook increased to reflect US tariff refund
27/07/2026 -
ProMIS Neurosciences to Host Webinar to Discuss Upcoming 6-Month Blinded Interim Data from PRECISE-AD Phase 1b Trial of PMN310 in Alzheimer’s Disease
27/07/2026 -
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
27/07/2026 -
Carlsmed, Inc. To Participate in Upcoming Investor Conferences
27/07/2026
Pages